Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib SR in Myelofibrosis
NCT01340651Phase 2Completed
- Sponsor
- Incyte
- Start
- Mar 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in myelofibrosis (MF), sponsored by Incyte. Primary endpoints: Percentage of Participants With at Least 1 Adverse Event and Overall Response (OR) at Week 16. Started Mar 2011; status: completed.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01340651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01340651.